Equillium (EQ) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Equillium (EQ) has outperformed Tiziana Life Sciences (TLSA) over the past year, gaining 10.4% versus a loss of 64.3%. Over five years, TLSA leads with a -53.0% price change compared with -80.4% for EQ. Equillium is the larger company by market cap ($87.3 million vs $79.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EQ | TLSA |
|---|---|---|
| Share price | $1.06 | $0.6206 |
| Market cap | $87.26M | $79.45M |
| 1-day change | -5.36% | -8.14% |
| YTD return | -31.61% | -58.35% |
| 1-year return | +10.42% | -64.33% |
| 5-year return | -80.41% | -52.98% |
| EPS (TTM) | $-0.12 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-22.40M | $-11.86M |
| 52-week high | $3.54 | $1.90 |
| 52-week low | $0.81 | $0.55 |
| Distance from 52-week high | -70.06% | -67.34% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +707.55% | +1203.58% |
| Average volume | 544.39K | 606.04K |
| Shares outstanding | 82.32M | 128.03M |
| Employees | 14 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EQ has outperformed TLSA by 74.8 percentage points over the past year.
About Equillium
EQ stock →Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
EQ vs TLSA FAQ
Which is bigger, Equillium or Tiziana Life Sciences?
Equillium (EQ) is larger, with a market capitalization of $87.26M compared with $79.45M for Tiziana Life Sciences (TLSA).
Which stock has performed better over the past year, EQ or TLSA?
EQ returned +10.42% over the past 12 months, compared with -64.33% for TLSA (price return, excluding dividends). Past performance does not predict future results.
Are Equillium and Tiziana Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.